PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

First patient dosed in Immutep’s soft tissue sarcoma trial

The phase 2 study involves the company’s eftilagimod alpha therapy.

Immutep – a company focused on developing novel LAG-3 immunotherapies for cancer and autoimmune diseases – has announced that the first patient has been dosed in its EFTISARC-NEO trial.

The phase 2 study involves the company’s eftilagimod alpha (efti) therapy – a soluble LAG-3 protein and major histocompatibility complex (MHC) class II agonist, in combination with radiotherapy and the anti-PD-1 therapy Keytruda, for patients with soft tissue sarcoma.

It also becomes the first chemo-free trial to analyse efti in a neoadjuvant situation.

The study, which will treat up to 40 patients, is being conducted by the Maria Sk?odowska-Curie National Research Institute of Oncology and is mainly financed using a grant from the Polish Medical Research Agency programme.

Principal investigator, Dr Pawe? Sobczuk, was in no doubt about the importance of the trial: “Soft tissue sarcoma is a rare, aggressive disease in high need of new therapeutic approaches, and we are pleased to begin treating patients with this novel IO-IO-radiotherapy combination and look forward to evaluating the potential synergistic effects of this chemo-free therapy.”

He added: “In particular, efti’s sustained activation of antigen-presenting cells, leading to the proliferation of activated CD8+ T cells and elevated interferon-gamma levels, may transform the immunosuppressed tumour microenvironment of soft tissue sarcomas into one that enables immune checkpoint inhibitors like pembrolizumab to exert their anti-cancer effect.”

CSO at Immutep, Frédéric Triebel, reflected: “The neoadjuvant setting gives us the opportunity to assess in the surgical specimen the changes in the tumour microenvironment induced by efti. New information arising from this innovative trial may further broaden the future clinical development of efti and, in the end, bring even greater benefit to patients.”

Soft tissue sarcoma represents a serious condition with high unmet needs and a poor prognosis. The prevalence of illness varies across regions, with approximately 23,400 cases annually and an incidence of 4.7 per 100,000 throughout Europe.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026